Ocuphire Pharma, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Farmington Hills MI United States (2018)
Status: Acquired by Rexahn Pharmaceuticals, Inc. (2020)

Organization Overview

First Clinical Trial
2018
NCT04004507
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ocuphire Pharma, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Ocuphire Pharma, Inc. (0) Acquired (1)

phentolamine mesylate (regitine) (7 trials)

Drugs in Phase 2 Trials (7)

Key: Ocuphire Pharma, Inc. (0) Acquired (7)

apx3330 (1 trial)

clavulanate (Augmentin) (3 trials)

everolimus (zortress) (1 trial)

fluorocyclopentenylcytosine (2 trials)

gemcitabine (gemzar) (1 trial)

pilocarpine (ocusert) (1 trial)

rx-0201 (2 trials)

Drugs in Phase 1 Trials (1)

Key: Ocuphire Pharma, Inc. (0) Acquired (1)

rx-5902 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Dilatation, Pathologic (Phase 3)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Macular Edema (Phase 2)

Mydriasis (Phase 3)

Ocular Hypertension (Phase 2)

Presbyopia (Phase 2)

Retinal Diseases (Phase 2)

Vision Disorders (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 16
  • # of Trial APIs: 9